Arilin

PreclinicalSmall molecule

CClinical Research Center Kiel GmbH

Arilin is one of 19 small molecule programs targeting Bacterial Vaginosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial VaginosisActive, not recruiting

Bacterial VaginosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Bacterial Vaginosis

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

25 2

Acanya

Pfizer

Approved

3 3

Decadron

AAspen Global Incorporated

Approved

—4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Mycostatin

Lactobacillus Acidophilus

UUniversiteit Antwerpen

Approved

1 7

Tindamax

MMission Pharmacal

Phase 3

3 8

Conventional

PPopulation Health Research Institute

Phase 3

1 9

Lactoferrin

UUniversità degli Studi di Ferrara

Phase 3

1 10

Lactoserum

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Vaginosis1 trial

Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis

Completed·—·N/A·NCT02744638·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Arilin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Arilin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Arilin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clinical Research Center Kiel GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CClinical Research Center Kiel GmbH

Arilin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Vaginosis1 trial

References

Drug Info

Quick Facts

Related News